Aptevo Therapeutics Inc.
APVO
$4.30
-$0.48-10.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -151.47% | -100.00% | -102.42% | -100.98% | -100.40% |
| Gross Profit | 151.47% | 100.00% | 102.42% | 100.98% | 100.40% |
| SG&A Expenses | -13.79% | -13.14% | -12.29% | -12.22% | -16.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.26% | -14.81% | -18.47% | -17.36% | -8.71% |
| Operating Income | 14.26% | 14.81% | 18.47% | 17.36% | 8.71% |
| Income Before Tax | 13.21% | -29.38% | -36.30% | -32.23% | -263.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.21% | -29.38% | -36.30% | -32.23% | -263.39% |
| Earnings from Discontinued Operations | -- | -- | -80.03% | -82.05% | -83.55% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.27% | -38.58% | -46.87% | -42.91% | -246.07% |
| EBIT | 14.26% | 14.81% | 18.47% | 17.36% | 8.71% |
| EBITDA | 13.83% | 14.35% | 18.13% | 16.86% | 7.81% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |